Sector News

Teva to move global HQ to Tel Aviv amid $3B cost-cutting drive

December 14, 2018
Life sciences

Teva has already decided to move its U.S. headquarters, and now it’s planning to move its worldwide headquarters, too.

The company will relocate to Tel Aviv from Petah Tikvah, Israel in mid-2020—after it builds an office building there, a spokeswoman confirmed by email. Teva has chosen a site in the city’s Ramat Hahayal district, and the new structure will house only Teva employees. Teva will be leasing the building.

The reasoning behind the move is no surprise, given the generics giant is in the midst of implementing a $3 billion cost-cutting drive. Putting Teva’s headquarters under one roof—instead of at sites scattered around Petah Tikva—will save the company money, the spokeswoman said.

“Combining into one site … will be an efficient and cost-effective solution, generating significant savings from a business and operations point of view,” she wrote, adding that it will also “fulfill our goal of working as One Teva.”

As part of CEO Kåre Schultz’s grand restructuring, unveiled this time last year to help the company out of immense debt, Teva also agreed this summer to an address change in the U.S. after shuttering pricey offices in New York and Washington, D.C. Lured by a $40 million tax break from the state of New Jersey, the company switched its home base to Parsippany from North Wales, Pennsylvania.

There, it also has a construction project to complete. “It is an astronomical build-out process,” Harvey Rosenblatt, founder of the real estate developer that owns and manages Teva’s new building, told NJ.com in July.

Meanwhile, as Globes pointed out, the Tel Aviv news is likely to go over well in Israel’s home country, where concerns have persisted—thanks in part to the hiring of Danish Schultz, as well as plenty of local layoffs—that Teva is losing its Isareli identity and could even relocate to a new country.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach